HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

• Main Authors: Heather A. Prentice, Philip K. Ehrenberg, Karen M. Baldwin, Aviva Geretz, Charla Andrews, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Robert J. O'Connell, Merlin L. Robb, Jerome H. Kim, Nelson L. Michael, Rasmi Thomas
• Other Authors: Walter Reed Army Institute of Research
• Format: Article
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/33489
• Institution: Mahidol University

RV144 is the first phase 3 HIV vaccine clinical trial to demonstrate efficacy. This study consisted of more than 8,000 individuals in each arm of the trial, representing the four major regions of Thailand. Human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptor (KIR) genes...